ALISO VIEJO, Calif. - Valeant Pharmaceuticals International announced Tuesday that it signed an agreement to sell its manufacturing facilities in Humacao, Puerto Rico, and Basel, Switzerland, to Legacy Pharmaceuticals International.
Terms of the transaction were not disclosed.
Timothy C. Tyson, Valeant’s president and CEO, said, “The sale of the two manufacturing sites in Basel and Humacao represents the final step in our restructuring initiative, most of which was completed last year. We continue to make excellent progress toward the achievement of our metric goals.”
Valeant Pharmaceuticals International is a specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products primarily in the areas of neurology, infectious disease and dermatology.